Thursday, August 29, 2024 11:59:26 AM
On a more general low float runner note; people always complain about "dilution" in penny stocks. But the reality is, if it's not a complete scam company who are just selling their shares into the pump, they have to issue more shares for there to be an increase in share price with the increase in attention and volume. These things don't really move up much or best case run way up with only a 1.5 million float. If I had got in and was down 30-50% I would just hang around and wait. I'm going to keep an eye on it anyway. An analyst, H.C. Wainright, whoever the hell that is, has put a price target of $25 per share on this thing. So, who knows.
cheers!
Recent BCDA News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:00:08 PM
- BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures • GlobeNewswire Inc. • 04/28/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:04:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 12:00:09 PM
- BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:30:15 PM
- BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure • GlobeNewswire Inc. • 04/02/2026 02:11:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:05:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 08:31:26 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/24/2026 08:30:33 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/24/2026 08:05:25 PM
- BioCardia Reports 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/19/2026 11:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 10:02:10 AM
- BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA • GlobeNewswire Inc. • 03/17/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 01:01:30 PM
- BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 02:15:23 PM
- BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart • GlobeNewswire Inc. • 02/10/2026 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:47:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 01:00:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/18/2025 10:13:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 01:00:11 PM
- BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA • GlobeNewswire Inc. • 12/16/2025 01:00:00 PM
